Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

[ LAB] SCH66336

Known as: SCH-66336, SCH66336, SCH 66336 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
In this study, we have characterized a panel of NSCLC cell lines with differential sensitivity to gefitinib for activating… Expand
Highly Cited
2004
Highly Cited
2004
Ras farnesyltransferase inhibitor (FTI) exhibit antiproliferative and antiangiogenic effects through a mechanism that is poorly… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2002
Highly Cited
2002
The development of chronic myeloid leukemia (CML) is dependent on the deregulated tyrosine kinase of the oncoprotein BCR-ABL… Expand
  • figure 1
  • figure 2
Highly Cited
2001
Highly Cited
2001
The Philadelphia (Ph) chromosome is found in approximately 3% of pediatric patients with acute lymphoblastic leukemia (ALL) and… Expand
  • figure 1
  • figure 4
  • figure 2
  • figure 3
  • figure 5
Highly Cited
2001
Highly Cited
2001
BCR/ABL, the oncoprotein responsible for chronic myeloid leukemia (CML), transforms hematopoietic cells through both Ras… Expand
Highly Cited
2001
Highly Cited
2001
The enzyme protein farnesyltransferase, which catalyzes the first step in the posttranslational modification of ras and a number… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2000
Highly Cited
2000
Farnesyl protein transferase (FT), an enzyme that catalyzes the first step in the posttranslational modification of ras and a… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2000
Highly Cited
2000
Purpose: SCH66336 is an orally active, farnesyl protein transferase inhibitor. SCH66336 inhibits ras farnesylation in tumor cells… Expand
Highly Cited
2000
Highly Cited
2000
Farnesyltransferase inhibitors (FTIs) were developed to target abnormal signaling pathways that are commonly activated in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
1998
Highly Cited
1998
We have been developing a series of nonpeptidic, small molecule farnesyl protein transferase inhibitors that share a common… Expand
  • table 1
  • table 2
  • table 3
  • figure I
  • table 4